$29MSeries B, 9 February 2026
Closed a $29M (KRW 42B) Series B to enhance its AI design platform, expand R&D and advance preclinical pipelines.
- Amount
- $29M
- Stage
- Series B
- Announced
- 9 February 2026
- Lead
- DAYLI Partners
- Other investors
- InterVest, PATHWAY Investment, Yuanta Investment, Korea Development Bank, SL Investment, Korea Investment & Securities
- Use of funds
- Closed a $29M (KRW 42B) Series B to enhance its AI design platform, expand R&D and advance preclinical pipelines.
- Checked
- Announced by the company
- Sources
- Galux raises $29M Series B for AI-driven protein design in drug discovery businesswire.com
Galux raises $29M Series B for AI-driven protein design in drug discovery techstartups.com